O	0	8	Protocol
O	9	12	for
O	13	16	the
O	17	18	"
O	18	28	Chemobrain
O	29	31	in
O	32	38	Motion
O	39	40	-
O	41	46	study
O	46	47	"
O	48	49	(
O	49	52	CIM
O	53	54	-
O	55	60	study
O	60	61	)
O	61	62	:
O	63	64	a
O	65	75	randomized
O	76	83	placebo
O	83	84	-
O	84	94	controlled
O	95	100	trial
O	101	103	of
O	104	107	the
O	108	114	impact
O	115	117	of
O	118	119	a
B-intervention	120	124	high
I-intervention	124	125	-
I-intervention	125	134	intensity
I-intervention	135	143	interval
I-intervention	144	153	endurance
I-intervention	154	162	training
O	163	165	on
O	166	172	cancer
O	173	180	related
O	181	190	cognitive
O	191	202	impairments
O	203	205	in
O	206	211	women
O	212	216	with
O	217	223	breast
O	224	230	cancer
O	231	240	receiving
O	241	246	first
O	246	247	-
O	247	251	line
O	252	264	chemotherapy
O	264	265	.

O	266	268	Up
O	269	271	to
O	272	274	80
O	274	275	%
O	276	278	of
O	279	285	breast
O	286	292	cancer
O	293	301	patients
O	302	308	suffer
O	309	313	from
O	314	320	Cancer
O	321	328	Related
O	329	338	Cognitive
O	339	350	Impairments
O	351	352	(
O	352	356	CRCI
O	356	357	)
O	357	358	.

O	359	367	Exercise
O	368	370	is
O	371	380	suggested
O	381	383	as
O	384	385	a
O	386	395	potential
O	396	406	supportive
O	407	411	care
O	412	418	option
O	419	421	to
O	422	428	reduce
O	429	438	cognitive
O	439	446	decline
O	447	449	in
O	450	456	cancer
O	457	465	patients
O	465	466	.

O	467	471	This
O	472	477	study
O	478	482	will
O	483	494	investigate
O	495	498	the
O	499	506	effects
O	507	509	of
O	510	511	a
O	512	516	high
O	516	517	-
O	517	526	intensity
O	527	535	interval
O	536	545	endurance
O	546	554	training
O	555	556	(
O	556	560	HIIT
O	560	561	)
O	562	564	on
O	565	569	CRCI
O	570	572	in
O	573	579	breast
O	580	586	cancer
O	587	595	patients
O	595	596	.

O	597	608	Potentially
O	609	619	underlying
O	620	633	immunological
O	634	637	and
O	638	653	neurobiological
O	654	664	mechanisms
O	664	665	,
O	666	668	as
O	669	673	well
O	674	676	as
O	677	684	effects
O	685	687	on
O	688	696	patients
O	696	697	'
O	698	702	self
O	702	703	-
O	703	712	perceived
O	713	722	cognitive
O	723	734	functioning
O	735	738	and
O	739	745	common
O	746	752	cancer
O	753	760	related
O	761	765	side
O	765	766	-
O	766	773	effects
O	773	774	,
O	775	779	will
O	780	782	be
O	783	791	explored
O	791	792	.

O	793	794	A
O	795	801	single
O	801	802	-
O	802	809	blinded
O	810	820	randomized
O	821	831	controlled
O	832	837	trial
O	838	842	will
O	843	845	be
O	846	853	carried
O	854	857	out
O	857	858	.

O	859	862	The
O	863	869	impact
O	870	872	of
O	873	877	HIIT
O	878	880	on
O	881	885	CRCI
O	886	890	will
O	891	893	be
O	894	902	compared
O	903	905	to
O	906	910	that
O	911	913	of
O	914	915	a
B-control	916	923	placebo
I-control	923	924	-
I-control	924	936	intervention
I-control	937	938	(
I-control	938	948	supervised
I-control	949	959	myofascial
I-control	960	967	release
I-control	968	976	training
I-control	976	977	)
O	977	978	.

O	979	983	Both
O	984	997	interventions
O	998	1002	will
O	1003	1005	be
O	1006	1015	conducted
O	1016	1030	simultaneously
O	1031	1035	with
O	1036	1039	the
O	1040	1048	patients
O	1048	1049	'
O	1050	1055	first
O	1055	1056	-
O	1056	1060	line
O	1061	1073	chemotherapy
O	1074	1083	treatment
O	1084	1093	typically
O	1094	1101	lasting
O	1102	1104	12
O	1104	1105	-
O	1105	1107	18
O	1108	1113	weeks
O	1113	1114	.

B-total-participants	1115	1120	Fifty
I-total-participants	1120	1121	-
I-total-participants	1121	1125	nine
B-eligibility	1126	1131	women
I-eligibility	1132	1136	with
I-eligibility	1137	1143	breast
I-eligibility	1144	1150	cancer
O	1151	1155	will
O	1156	1158	be
O	1159	1167	included
O	1168	1170	in
O	1171	1175	each
O	1176	1178	of
O	1179	1182	the
O	1183	1186	two
O	1187	1193	groups
O	1193	1194	.

O	1195	1198	The
O	1199	1204	study
O	1205	1207	is
O	1208	1215	powered
O	1216	1218	to
O	1219	1225	detect
O	1226	1227	(
O	1227	1228	α
O	1229	1230	=
O	1231	1232	.
O	1232	1234	05
O	1234	1235	,
O	1236	1237	β
O	1238	1239	=
O	1240	1241	.
O	1241	1242	2
O	1242	1243	)
O	1244	1245	a
O	1246	1252	medium
O	1253	1259	effect
O	1260	1264	size
O	1265	1275	difference
O	1276	1283	between
O	1284	1287	the
O	1288	1291	two
O	1292	1298	groups
O	1299	1300	(
O	1300	1301	d
O	1302	1303	=
O	1304	1305	.
O	1305	1306	5
O	1306	1307	)
O	1308	1310	in
O	1311	1316	terms
O	1317	1319	of
O	1320	1328	patients
O	1328	1329	'
O	1330	1336	change
O	1337	1339	in
O	1340	1349	cognitive
O	1350	1357	testing
O	1358	1370	performances
O	1370	1371	,
O	1372	1376	from
O	1377	1385	baseline
O	1386	1391	until
O	1392	1395	the
O	1396	1399	end
O	1400	1402	of
O	1403	1406	the
O	1407	1415	exercise
O	1415	1416	-
O	1416	1428	intervention
O	1428	1429	.

O	1430	1433	The
B-outcome-Measure	1434	1443	cognitive
I-outcome-Measure	1444	1448	test
I-outcome-Measure	1449	1456	battery
O	1456	1457	,
O	1458	1469	recommended
O	1470	1472	by
O	1473	1476	the
O	1477	1490	International
O	1491	1497	Cancer
O	1498	1501	and
O	1502	1511	Cognition
O	1512	1516	Task
O	1517	1522	Force
O	1523	1525	to
O	1526	1532	assess
O	1533	1537	CRCI
O	1537	1538	,
O	1539	1543	will
O	1544	1546	be
O	1547	1551	used
O	1552	1554	as
O	1555	1562	primary
O	1563	1570	measure
O	1570	1571	.

O	1572	1576	This
O	1577	1585	includes
O	1586	1589	the
O	1590	1597	Hopkins
O	1598	1604	Verbal
O	1605	1613	Learning
O	1614	1618	Test
O	1619	1620	(
O	1620	1628	learning
O	1628	1629	/
O	1629	1635	verbal
O	1636	1642	memory
O	1642	1643	)
O	1643	1644	,
O	1645	1648	the
O	1649	1659	Controlled
O	1660	1664	Oral
O	1665	1669	Word
O	1670	1681	Association
O	1682	1686	Test
O	1687	1688	(
O	1688	1694	verbal
O	1695	1702	fluency
O	1702	1703	)
O	1704	1707	and
O	1708	1711	the
O	1712	1717	Trail
O	1717	1718	-
O	1718	1724	Making
O	1724	1725	-
O	1725	1729	Test
O	1730	1731	A
O	1731	1732	/
O	1732	1733	B
O	1734	1735	(
O	1735	1744	attention
O	1744	1745	/
O	1745	1748	set
O	1748	1749	-
O	1749	1758	switching
O	1758	1759	)
O	1759	1760	.

O	1761	1764	The
O	1765	1774	following
O	1775	1784	endpoints
O	1785	1789	will
O	1790	1792	be
O	1793	1801	assessed
O	1802	1804	as
O	1805	1814	secondary
O	1815	1823	measures
O	1823	1824	:
O	1825	1827	Go
O	1827	1828	-
O	1828	1829	/
O	1829	1831	No
O	1831	1832	-
O	1832	1834	Go
O	1835	1839	test
O	1840	1851	performance
O	1852	1853	(
O	1853	1861	response
O	1862	1872	inhibition
O	1872	1873	)
O	1873	1874	,
O	1875	1879	self
O	1879	1880	-
O	1880	1889	perceived
O	1890	1899	cognitive
O	1900	1911	functioning
O	1911	1912	,
O	1913	1918	serum
O	1919	1925	levels
O	1926	1928	of
O	1929	1932	pro
O	1932	1933	-
O	1934	1937	and
O	1938	1954	antiinflammatory
O	1955	1962	markers
O	1963	1964	(
O	1964	1969	tumor
O	1970	1978	necrosis
O	1979	1985	factor
O	1986	1991	alpha
O	1991	1992	,
O	1993	2004	Interleukin
O	2004	2005	-
O	2005	2006	6
O	2006	2007	,
O	2008	2019	Interleukin
O	2019	2020	-
O	2020	2021	1
O	2022	2027	alpha
O	2027	2028	,
O	2029	2040	Interleukin
O	2040	2041	-
O	2041	2042	1
O	2043	2047	beta
O	2047	2048	,
O	2049	2050	C
O	2050	2051	-
O	2051	2059	reactive
O	2060	2067	protein
O	2067	2068	,
O	2069	2080	Interleukin
O	2080	2081	-
O	2081	2082	1
O	2083	2091	receptor
O	2092	2102	antagonist
O	2103	2106	and
O	2107	2118	Interleukin
O	2118	2119	-
O	2119	2121	10
O	2121	2122	)
O	2122	2123	,
O	2124	2129	serum
O	2130	2136	levels
O	2137	2139	of
O	2140	2152	neurotrophic
O	2153	2156	and
O	2157	2163	growth
O	2164	2171	factors
O	2172	2173	(
O	2173	2178	brain
O	2178	2179	-
O	2179	2186	derived
O	2187	2199	neurotrophic
O	2200	2206	factor
O	2206	2207	,
O	2208	2215	insulin
O	2215	2216	-
O	2216	2220	like
O	2221	2227	growth
O	2228	2234	factor
O	2235	2236	1
O	2237	2240	and
O	2241	2249	vascular
O	2250	2261	endothelial
O	2262	2268	growth
O	2269	2275	factor
O	2275	2276	)
O	2276	2277	,
O	2278	2280	as
O	2281	2285	well
O	2286	2288	as
O	2289	2295	common
O	2296	2302	cancer
O	2302	2303	-
O	2303	2310	related
O	2311	2315	side
O	2316	2323	effects
O	2324	2325	(
O	2325	2333	decrease
O	2334	2336	in
O	2337	2345	physical
O	2346	2354	capacity
O	2354	2355	,
O	2356	2363	fatigue
O	2363	2364	,
O	2365	2372	anxiety
O	2373	2376	and
O	2377	2387	depression
O	2387	2388	,
O	2389	2394	sleep
O	2395	2407	disturbances
O	2407	2408	,
O	2409	2416	quality
O	2417	2419	of
O	2420	2424	life
O	2425	2428	and
O	2429	2441	chemotherapy
O	2442	2452	compliance
O	2452	2453	)
O	2453	2454	.

O	2455	2459	This
O	2460	2465	study
O	2466	2470	will
O	2471	2478	provide
O	2479	2483	data
O	2484	2486	on
O	2487	2490	the
O	2491	2499	question
O	2500	2507	whether
O	2508	2512	HIIT
O	2513	2515	is
O	2516	2518	an
O	2519	2528	effective
O	2529	2539	supportive
O	2540	2547	therapy
O	2548	2552	that
O	2553	2563	alleviates
O	2564	2568	CRCI
O	2569	2571	in
O	2572	2578	breast
O	2579	2585	cancer
O	2586	2594	patients
O	2594	2595	.

O	2596	2604	Moreover
O	2604	2605	,
O	2606	2609	the
O	2610	2617	present
O	2618	2623	study
O	2624	2628	will
O	2629	2633	help
O	2634	2638	shed
O	2639	2644	light
O	2645	2647	on
O	2648	2651	the
O	2652	2662	underlying
O	2663	2673	mechanisms
O	2674	2676	of
O	2677	2686	potential
O	2687	2691	CRCI
O	2692	2701	improving
O	2702	2709	effects
O	2710	2712	of
O	2713	2721	exercise
O	2722	2724	in
O	2725	2731	breast
O	2732	2738	cancer
O	2739	2747	patients
O	2747	2748	.

O	2749	2753	DRKS
O	2753	2754	.
O	2754	2756	de
O	2756	2757	,
O	2758	2764	German
O	2765	2773	Clinical
O	2774	2780	Trials
O	2781	2789	Register
O	2790	2791	(
O	2791	2795	DRKS
O	2795	2796	)
O	2796	2797	,
O	2798	2800	ID
O	2800	2801	:
O	2802	2814	DRKS00011390
O	2815	2816	,
O	2817	2827	Registered
O	2828	2830	on
O	2831	2833	17
O	2834	2841	January
O	2842	2846	2018
O	2846	2847	.
